x-no-archive: yes
"NOTE: To view the article with Web enhancements, go to:
http://www.medscape.com/viewarticle/555989
"May 3, 2007 — Spectroscopic measurement of dermal advanced glycation
end products (AGEs) is a more effective and noninvasive technology for
prediabetes and diabetes screening compared with fasting plasma glucose
and glycated hemoglobin (A1c) tests, according to the results of a study
published in the May issue of Diabetes Care.
"This study compared the performance of a novel noninvasive technology
to fasting plasma glucose (FPG) and A1C tests for detecting undiagnosed
diabetes and impaired glucose tolerance," write John D. Maynard, MS,
from VeraLight in Albuquerque, New Mexico, and colleagues. "Current
screening methods for type 2 diabetes and pre-diabetes are inadequate
due to their inconvenience and inaccuracy.... A more accurate and
convenient screening method could dramatically improve early detection
of type 2 diabetes and its precursors, facilitating interventions that
can prevent or at least delay the development of type 2 diabetes and its
related micro- and macrovascular complications."
Elevated skin AGEs are biomarkers of diabetes, are highly correlated
with the complications of diabetes, and predict future diabetic
retinopathy and nephropathy. Individuals with diabetes accumulate skin
AGEs faster than do individuals with normal glucose regulation. Until
the recent development of novel noninvasive technology to measure AGEs,
a punch biopsy was needed to quantify skin AGE levels. Spectroscopic
measurement of dermal AGEs (SAGE) measures skin fluorescence caused by
AGEs and provides a quantitative diabetes risk score. It does not
require fasting, creates no biohazards, automatically compensates for
subject-specific skin differences, and provides an immediate result.
This head-to-head evaluation in a naive population of 351 subjects
compared results from FPG and A1C tests with results from testing with a
noninvasive device that detects the fluorescence of skin AGEs."